secwatch.observer — SEC 8-K summary
======================================

Issuer:     TREACE MEDICAL CONCEPTS, INC. (TMCI)
CIK:        0001630627
Form:       8-K
Filed at:   2026-04-09T23:59:59+00:00
Accession:  0001630627-26-000010
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 7.01, 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Treace prelim Q1 rev $47.0-47.2M; FY26 guidance raised to $202-212M; CCO departs
--------------------------------------------------------------------------------

- Preliminary Q1 revenue expected $47.0-47.2M; cash $51.9M, up $3.5M from Dec 2025.
- Full-year 2026 revenue guidance updated to $202-212M vs prior $200-212M.
- Chief Commercial Officer Gaetano Guglielmino departed April 8; role not replaced.
- CCO to consult through Jan 2027; $36,667/month fee, COBRA, prorated bonus, equity vest.
- SVP Sales will now report directly to CEO John Treace.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1630627/000163062726000010/0001630627-26-000010-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1630627/000163062726000010/tmci-20260408.htm
  HTML page:      https://secwatch.observer/filing/0001630627-26-000010

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer